S. Galbraith

发表

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

Pierre Validire, Yudi Pawitan, Angel Porgador, 2015, Oncotarget.

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry

J. Schellens, J. Beijnen, R. C. Garner, 2007, Investigational New Drugs.

Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies

R. Boellaard, A. Lammertsma, O. Hoekstra, 2009, Journal of Nuclear Medicine.

Identification and validation of phospho-SRC, a novel and potential pharmacodynamic biomarker for dasatinib (SPRYCEL™), a multi-targeted kinase inhibitor

F. Lee, S. Galbraith, Y. Barrett, 2008, Cancer Chemotherapy and Pharmacology.

The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases

J. Fargnoli, J. Barrish, J. Hunt, 2010, Molecular Cancer Therapeutics.

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.

F. Lee, B. Vojnovic, M. Stratford, 2001, Anticancer research.

ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature.

D. Blakey, M. Stratford, G. Tozer, 2002, Cancer research.

5,6-Dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study

G. Rustin, P. Loadman, L. Gumbrell, 2003, British Journal of Cancer.

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.

P. Price, G. Rustin, L. Gumbrell, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of quality assurance, centralized analysis, ROI method and glucose correction on SUV test-retest variability in a multi-center setting

Ronald Boellaard, Georgia Kollia, Adriaan Lammertsma, 2009 .

Report from the SWOG Radiation Oncology Committee: Research Objectives Workshop 2017

Charles R. Thomas, P. Spellman, P. Okunieff, 2018, Clinical Cancer Research.

Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development

J. Armenia, A. Lau, M. O’Connor, 2021, Molecular Cancer Therapeutics.

Effects o f 5 ,6-Dimethylxant henone-4-Acetic A cid o n H uman Tumor M icrocirculation A ssessed b y D ynamic C ontrast- Enhanced M agnetic R esonance I maging

A. Padhani, G. Rustin, M. Lodge, 2002 .

Imaging the Effects of Vasculature‐targeting Agents

S. Galbraith, 2006 .

A phase I study of BMS-582664 (brivanib alaninate), an oral dual inhibitor of VEGFR and FGFR tyrosine kinases, in patients (pts) with advanced/metastatic solid tumors: Safety, pharmacokinetic (PK), and pharmacodynamic (PD) findings

G. Jayson, M. Sawyer, G. Rustin, 2007 .

Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non–Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies

J. Blay, R. Schilsky, S. Ikeda, 2022, JCO precision oncology.

Ipilimumab Increases Activated T Cells and Enhances Humoral Immunity in Patients With Advanced Melanoma

S. Chasalow, S. Gnjatic, S. Galbraith, 2012, Journal of immunotherapy.

Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors.

M. Ayers, G. Wilding, L. Rosen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: A retrospective analysis.

C. Horak, J. Baselga, F. Lee, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potential immune biomarkers of gastrointestinal toxicities and efficacy in patients with advanced melanoma treated with ipilimumab with or without prophylactic budesonide

S. Chasalow, Z. Tsuchihashi, S. Galbraith, 2008 .

Comorbidity between lung cancer and COVID-19 pneumonia: role of immunoregulatory gene transcripts in high ACE2-expressing normal lung

J. Blay, R. Schilsky, S. Ikeda, 2022, Therapeutic advances in medical oncology.

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

W. Humphreys, F. Lee, A. Allentoff, 2008, Drug Metabolism and Disposition.

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.

Martin A Lodge, R. Maxwell, A. Padhani, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.

S. Targan, S. Chasalow, Hanlin L. Wang, 2010, Cancer immunity.

The changing world of oncology drug development-A global pharmaceutical company's perspective.

S. Galbraith, Susan Galbraith, 2014, Chinese clinical oncology.

Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.

A. Padhani, G. Rustin, M. Lodge, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer

G. Sledge, A. Wolff, J. Sparano, 2004, Clinical Cancer Research.

Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy

W. Hayes, D. Nuyten, J. Marshall, 2011, British Journal of Cancer.

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer.

J. Baselga, E. Kubista, Li-an Xu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Porto European Cancer Research Summit 2021

S. Fröhling, D. Hanahan, J. Korbel, 2021, Molecular oncology.

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors.

G. Jayson, M. Sawyer, G. Rustin, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Correlation of FGF2 tumor expression with tumor response, PFS, and changes in plasma pharmacodynamic (PD) markers following treatment with brivanib alaninate, an oral dual inhibitor of VEGFR and FGFR tyrosine kinases

G. Jayson, S. Galbraith, D. Jonker, 2008 .

Predictive biomarker discovery and validation for the targeted chemotherapeutic ixabepilone.

J. Baselga, Shujian Wu, Li-an Xu, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): Preliminary efficacy and safety data

J. Baselga, E. Kubista, G. Manikhas, 2005 .

Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.

S. Chasalow, Z. Tsuchihashi, S. Galbraith, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PET as a biomarker of the antitumor effects of the CDK2 inhibitor BMS-387032.

A. Fischman, R. Rubin, S. Galbraith, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MR in oncology drug development

S. Galbraith, Susan M. Galbraith, 2006, NMR in biomedicine.

Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.

A. Bezjak, L. Seymour, F. Shepherd, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18.

L. Seymour, F. Shepherd, D. Tu, 2004, Journal of Clinical Oncology.

Antivascular cancer treatments: imaging biomarkers in pharmaceutical drug development.

S. Galbraith, S M Galbraith, 2003, The British journal of radiology.

A Randomized Phase II Feasibility Trial of BMS-275291 in Patients with Early Stage Breast Cancer

G. Sledge, A. Wolff, J. Sparano, 2004, Clinical Cancer Research.